retatrutide clinical trial Seeking Differentiation Through a Triple Mechanism" Eli Lilly's Again Proves Efficacy in Trials, Raising Question of Whether It Can Overcome Side-Effect Limits and Reshape the Market Trial of next-gen weight-loss drug

Drug class: GIP/GLP-1/Glucagon receptor triagonist Route: Once-weekly subcutaneous injection Developer: Eli Lilly and Company Phase: Phase 3 (TRIUMPH program) Status: Investigational NOT TEY approved by FDA or EMA (despite what your online dealer told you ) Here's how it compares to the drugs most people already know: - Semaglutide (Ozempic/Wegovy): activates 1 receptor GLP-1 - Tirzepatide (Mounjaro/Zepbound): activates 2 receptors GLP-1 + GIP - Retatrutide: activates 3 receptors GLP-1 + GIP + Glucagon That third receptor the glucagon receptor is the differentiator

Store it in the refrigerator, keep it away from light, and it should maintain potency through this window

Wegovy is specifically approved for weight management in adults with obesity or overweight individuals with weight-related medical conditions

In the long-term, these dynamics are likely to partially or fully resolve

Non-GLP-1 weight loss medications offer alternatives for patients unable to tolerate GLP-1-related gastrointestinal effects

Stay in touch with your Member Success Team, who are dedicated to helping you reach your desired results